» Articles » PMID: 38533198

An Updated Review on Guillain-Barré Syndrome: Challenges in Infection Prevention and Control in Low- and Middle-income Countries

Overview
Journal SAGE Open Med
Publisher Sage Publications
Specialty General Medicine
Date 2024 Mar 27
PMID 38533198
Authors
Affiliations
Soon will be listed here.
Abstract

Guillain-Barré syndrome is a rare condition that can be potentially life-threatening. Guillain-Barré syndrome does not have a definitive etiological agent. It is a syndrome that can arise from multiple factors, including various infectious diseases and immunizations. The severity of Guillain-Barré syndrome is exacerbated by these variables, especially in low-income and middle-income countries where healthcare systems are already constrained and struggle to meet the demands of other diseases. The primary aim of our article is to comprehensively examine the life-threatening nature and intensity of Guillain-Barré syndrome by assessing its etiology, progression, and prevalence in low- and middle-income nations while also considering global trends. Furthermore, we proposed the implementation of standard and efficacious treatment and diagnostic resources that are readily accessible and successful in affluent nations and should also be readily accessible in impoverished nations without any unnecessary delay. Our study also emphasized the epidemiological data with molecular epidemiological analysis and the utilization of artificial technology in low- and middle-income nations. The goal was to decrease the incidence of Guillain-Barré syndrome cases and facilitate early detection.

Citing Articles

Causal relationship between immune cells and Guillain-Barré syndrome: a Mendelian randomization study.

Liu H, Shao S, Chen B, Yang S, Zhang X Front Neurol. 2024; 15:1446472.

PMID: 39600430 PMC: 11588641. DOI: 10.3389/fneur.2024.1446472.


Complete genome sequence of strain GBS0709 isolated from a Japanese patient with the acute motor axonal neuropathy subtype of Guillain-Barré syndrome.

Imajoh M, Mori M, Shimizu T, Koizumi Y, Kobayashi Y, Kawahara M Microbiol Resour Announc. 2024; 13(9):e0045624.

PMID: 39083684 PMC: 11385721. DOI: 10.1128/mra.00456-24.


Isolated Self-Limited Right Oculomotor Nerve Palsy With Positive Asialo-GM1 Antibody After SARS-CoV-2 mRNA Vaccination.

Ozobu I, Salter E, Salter S, Peng D, Sherbaf A, Ravinutala A Cureus. 2024; 16(7):e65045.

PMID: 39035598 PMC: 11260434. DOI: 10.7759/cureus.65045.

References
1.
Nyati K, Nyati R . Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. Biomed Res Int. 2013; 2013:852195. PMC: 3755430. DOI: 10.1155/2013/852195. View

2.
Kim A, Lee H, Lee Y, Kang H . Epidemiological Features and Economic Burden of Guillain-Barré Syndrome in South Korea: A Nationwide Population-Based Study. J Clin Neurol. 2021; 17(2):257-264. PMC: 8053545. DOI: 10.3988/jcn.2021.17.2.257. View

3.
Salmon D, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen D . Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013; 381(9876):1461-8. DOI: 10.1016/S0140-6736(12)62189-8. View

4.
Hughes R, Charlton J, Latinovic R, Gulliford M . No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006; 166(12):1301-4. DOI: 10.1001/archinte.166.12.1301. View

5.
Bragazzi N, Kolahi A, Nejadghaderi S, Lochner P, Brigo F, Naldi A . Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation. 2021; 18(1):264. PMC: 8581128. DOI: 10.1186/s12974-021-02319-4. View